Floatz logo

Anti-Muc1 Car-T Cells

Gastric Carcinoma

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Cell therapyPhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

49 Active assets in the Gastric Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
City of Hope Medical Center
Phase 1/2CCC
gsk1120212
National Cancer Institute (NCI)
Phase 2CCC
Dabrafenib
National Cancer Institute (NCI)
Phase 2CCC
TRASTUZUMAB
National Cancer Institute (NCI)
Phase 2CCC
Crizotinib
National Cancer Institute (NCI)
Phase 2CCC

View all 50 →

Same molecule, other indications

Anti-Muc1 Car-T Cells is also rated in:

brain gliomaDormant
CCC
Indicative ·
48 / 100
View asset →
esophageal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Lung Neoplasm MalignantDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →